QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

CRNX

QT57Crinetics Pharmaceuticals, Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
35.87
+0.12+0.34%
OverviewShort InterestFilings
CRNXQT57Crinetics Pharmaceuticals, Inc.·NASDAQ
OverviewShort InterestFilings
35.87+0.34%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-
Insider Own15.20%
Shs Outstand105.44M
Perf Week6.98%
Market Cap3.77BForward P/E-EPS next Y-4.21Insider Trans0.05%Shs Float-Perf Month2.66%
Enterprise Value3.70BPEG0.27EPS next Q-1.23Inst Own-Short Float-Perf Quarter0.14%
Income-502848632.00P/S208.62EPS this Y-Inst Trans-Short Ratio-Perf Half Y-26.21%
Sales18.07MP/B2.91EPS next Y12.42%ROA-35.42%Short Interest-Perf YTD-22.94%
Book/sh12.15P/C-EPS next 5Y-ROE-43.96%52W High57.99 -38.14%Perf Year16.27%
Cash/sh12.24P/FCF-EPS past 3/5Y-ROIC-40.83%52W Low25.83 38.87%Perf 3Y-
Dividend Est.-EV/EBITDA-7.53Sales past 3/5Y16.96% -Gross Margin98.89%Volatility3.12% 2.84%Perf 5Y-
Dividend TTM-EV/Sales204.94EPS Y/Y TTM-39.02%Oper. Margin-3020.32%ATR (14)1.69Perf 10Y-
Dividend Ex-Date-Quick Ratio18.56Sales Y/Y TTM-Profit Margin-2747.18%RSI (14)51.39Recom2.00
Dividend Gr. 3/5Y-Current Ratio18.60EPS Q/Q-18.27%SMA202.59%Beta1.10Target Price85.14
Payout0.00%Debt/Eq0.04Sales Q/Q-SMA50-3.64%Rel Volume1.76Prev Close35.75
Employees437LT Debt/Eq0.04EarningsAug 06SMA200-14.05%Avg Volume1.14MPrice35.87
IPO DateJul 18, 2018Option/ShortYes / YesEPS/Sales Surpr.-0.82% 22.22%Net Debt/EBITDA0.14Volume2,013,874Change0.34%
Analyst Ratings
DateActionAnalystRatingTarget
Jun-15-26ReiteratedH.C. Wainwright$69 → $81
May-15-26ReiteratedEvercore ISI$89 → $88
May-11-26ReiteratedOppenheimerOutperform$87 → $84
Jan-30-26ReiteratedStifel Nicolaus$75 → $84
Jan-12-26UpgradeGoldman SachsNeutral → Buy$36 → $67
Jan-08-26ReiteratedChina Renaissance Securities (US) Inc.$105
Jan-06-26ReiteratedMorgan StanleyOverweight$77 → $87
Jan-05-26ReiteratedEvercore ISI$80 → $90
Jan-05-26ReiteratedStifel Nicolaus$60 → $75
Sep-30-25ReiteratedOppenheimerOutperform$74 → $87
Latest News
Jun-15-26
Jun-15-2604:30PM
Crinetics Pharmaceuticals, Inc. (CRNX) Presents at Endocrine Society's Annual Meeting (ENDO 2026) - SlideshowSeekingAlpha
06:02AM
HC Wainwright & Co. Reiterates Buy on Crinetics Pharmaceuticals, Maintains $81 Price TargetBenzinga
02:55AM
Reported Sunday, Crinetics Presents Up To Two-Year PATHFNDR Open-Label Extension Data At ENDO 2026 Confirming PALSONIFY Maintains Stable IGF-1 Levels And Acromegaly Symptom ControlBenzinga
02:54AM
Reported Sunday, Crinetics Presents Phase 2 Data For Atumelnant In CAH Showing 67% Mean Reduction In Androstenedione Levels With 88% Of Participants Achieving Physiologic Glucocorticoid Dose At Week 12Benzinga
Jun-11-26
Jun-11-2610:21AM
Citizens Reiterates Market Outperform on Crinetics Pharmaceuticals, Maintains $95 Price TargetBenzinga
10:21AM
Citizens Reiterates Market Outperform on Crinetics Pharmaceuticals, Maintains $95 Price TargetBenzinga
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
FY 2017
12/31/2017
Total Revenue814
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A100
Gross Profit714
Selling, General and Administrative Excl. Other19110058
Research and Development332240169
Other Operating Expense000
Operating Income-517-339-223
Interest Expense
000
Unusual Expense
———
Non-Operating Income (Expense)-52-40-8
Net Income Before Taxes-465-298-215
Income Taxes
000
Consolidated Net Income-465-298-215
Net Income From Continuing Operations-465-298-215
Net Income-465-298-215
EPS (Recurring)-4.95-3.69-3.69
EPS (Basic, Before Extraordinaries)-4.95-3.69-3.69
EPS (Diluted)-4.95-3.69-3.69
EBITDA-461-296-213
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio546.96——
Gross Margin87.50100.00100.00
Operating Margin-6,462.50-33,900.00-5,575.00
Net Margin-5,812.50-29,800.00-5,375.00
Shares Outstanding948158
Market Capitalization4,376——
Operating Lease Expense
———
Insider Trading Volume
$38.78$34.40$30.02$25.63$21.25● Close Price0.00M0.85M1.71M2.56M3.42MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Knight Jeff E.Chief Dev. & Operating OfficerApr 08 '26Option Exercise22.42156,8683,517,636190,452Apr 10 12:00 AM
Knight Jeff E.Chief Dev. & Operating OfficerApr 08 '26Sale40.1085,1633,415,036105,289Apr 10 12:00 AM
Knight Jeff E.Chief Operating OfficerMar 16 '26Sale37.379,911370,412112,018Mar 18 12:00 AM
Betz Stephen F.Chief Scientific OfficerMar 16 '26Sale37.3710,612396,611137,101Mar 18 12:00 AM
Struthers Richard ScottPresident & CEOMar 16 '26Sale37.3721,981821,513404,778Mar 18 12:00 AM
Vivaldi Coelho RogerioDirectorMar 12 '26Sale36.155,000180,76116,300Mar 13 12:00 AM
Okey StephanieDirectorMar 03 '26Sale39.673,000119,01013,300Mar 04 12:00 AM
Schilke TobinChief Financial OfficerMar 03 '26Sale39.676,713266,30578,121Mar 04 12:00 AM
Kalofonos IsabelChief Commercial OfficerJan 05 '26Option Exercise40.595,000202,95097,500Jan 07 12:00 AM
Kalofonos IsabelChief Commercial OfficerJan 05 '26Sale55.002,500137,500834Jan 07 12:00 AM
Betz Stephen F.Chief Scientific OfficerDec 26 '25Option Exercise1.9136,00068,760117,713Dec 29 12:00 AM
Struthers Richard ScottPresident & CEODec 18 '25Option Exercise13.0989,4841,171,780364,759Dec 18 12:00 AM
Pizzuti DanaChief Med and Dev OfficerDec 01 '25Option Exercise16.8910,000168,90071,837Dec 03 12:00 AM
Pizzuti DanaChief Med and Dev OfficerDec 01 '25Sale45.025,000225,10066,837Dec 03 12:00 AM
Pizzuti DanaChief Med and Dev OfficerNov 03 '25Option Exercise16.8910,000168,90074,042Nov 05 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR